Lundbeck gets Japan marketing authorization for Vyepti to prevent migraines
Lundbeck said Japan’s MHLW granted marketing authorization for eptinezumab (Vyepti) for preventing migraine attacks in adults.
VALBY, Denmark, Sept. 16, 2026 // -- H. Lundbeck A/S (Lundbeck) today announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan has granted marketing authorization for eptinezumab for the prevention of migraine attacks in adults, marking an important milestone for patients…